REZOLUTE, INC. (RZLT) Scorecard
- 2026-Q2: Total return Win; Revenue growth No data; EPS growth No data.
- 2026-Q1: Total return Win; Revenue growth No data; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth No data; EPS growth Lose.
18/56
1.6 / 5 stars
All 56 Win/Lose results and 64 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 3 wins, 4 losses, 5 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/1 |
WinRZLT / S&P 70.49% / 15.20% |
No dataRZLT / S&P / 15.00% |
No dataRZLT / S&P / 50.40% |
| 2026-Q11/2 |
WinRZLT / S&P 29.24% / -4.33% |
No dataRZLT / S&P / 11.30% |
LoseRZLT / S&P -28.70% / 27.70% |
| 2025-Q40/2 |
LoseRZLT / S&P -74.89% / 2.65% |
No dataRZLT / S&P / 9.00% |
LoseRZLT / S&P -23.77% / 13.40% |
| 2025-Q31/2 |
WinRZLT / S&P 110.76% / 8.12% |
No dataRZLT / S&P / 4.61% |
LoseRZLT / S&P -26.77% / 13.45% |
| 2025-Q21/2 |
WinRZLT / S&P 53.79% / 10.94% |
No dataRZLT / S&P / 4.83% |
LoseRZLT / S&P -27.07% / 10.63% |
| 2025-Q10/2 |
LoseRZLT / S&P -40.82% / -4.27% |
No dataRZLT / S&P / 4.98% |
LoseRZLT / S&P 0.88% / 10.57% |
| 2024-Q41/2 |
LoseRZLT / S&P 1.03% / 2.41% |
No dataRZLT / S&P / 5.25% |
WinRZLT / S&P 10.91% / 6.15% |
| 2024-Q32/2 |
WinRZLT / S&P 12.79% / 5.89% |
No dataRZLT / S&P / 5.89% |
WinRZLT / S&P 16.51% / 6.11% |
| 2024-Q22/2 |
WinRZLT / S&P 68.63% / 4.28% |
No dataRZLT / S&P / 5.38% |
WinRZLT / S&P 33.00% / 5.12% |
| 2024-Q12/2 |
WinRZLT / S&P 156.80% / 10.56% |
No dataRZLT / S&P / 5.71% |
WinRZLT / S&P 48.05% / 5.59% |
| 2023-Q40/2 |
LoseRZLT / S&P -24.77% / 11.69% |
No dataRZLT / S&P / 6.81% |
LoseRZLT / S&P -1.79% / 7.78% |
| 2023-Q30/2 |
LoseRZLT / S&P -33.33% / -3.27% |
No dataRZLT / S&P / 7.52% |
LoseRZLT / S&P -34.34% / -5.03% |
| 2023-Q20/2 |
LoseRZLT / S&P 3.13% / 8.74% |
No dataRZLT / S&P / 9.50% |
LoseRZLT / S&P -58.16% / -8.57% |
| 2023-Q10/2 |
LoseRZLT / S&P -7.25% / 7.50% |
No dataRZLT / S&P / 10.77% |
LoseRZLT / S&P -75.56% / -15.69% |
| 2022-Q40/2 |
LoseRZLT / S&P -24.45% / 7.56% |
No dataRZLT / S&P / 11.88% |
LoseRZLT / S&P -61.90% / -17.99% |
| 2022-Q30/2 |
LoseRZLT / S&P -15.17% / -4.88% |
No dataRZLT / S&P / 13.47% |
LoseRZLT / S&P -45.03% / -1.41% |
| 2022-Q21/2 |
WinRZLT / S&P -4.44% / -16.10% |
No dataRZLT / S&P / 13.71% |
LoseRZLT / S&P -12.13% / 11.04% |
| 2022-Q10/1 |
LoseRZLT / S&P -29.29% / -4.60% |
No dataRZLT / S&P / 15.97% |
No dataRZLT / S&P / 42.23% |
| 2021-Q40/1 |
LoseRZLT / S&P -36.09% / 11.03% |
No dataRZLT / S&P / 15.00% |
No dataRZLT / S&P / 96.40% |
| 2021-Q30/1 |
LoseRZLT / S&P -47.59% / 0.58% |
No dataRZLT / S&P / 10.77% |
No dataRZLT / S&P / 69.42% |
| 2021-Q21/1 |
WinRZLT / S&P 102.12% / 8.55% |
No dataRZLT / S&P / 6.58% |
No dataRZLT / S&P / 51.81% |
| 2021-Q10/1 |
LoseRZLT / S&P -41.12% / 6.17% |
No dataRZLT / S&P / -1.06% |
No dataRZLT / S&P / 7.39% |
| 2020-Q40/1 |
LoseRZLT / S&P -44.36% / 12.15% |
No dataRZLT / S&P / -3.72% |
No dataRZLT / S&P / -33.42% |
| 2020-Q31/1 |
WinRZLT / S&P 363.44% / 8.93% |
No dataRZLT / S&P / -2.04% |
No dataRZLT / S&P / -27.10% |
| 2020-Q21/1 |
WinRZLT / S&P 32.86% / 20.54% |
No dataRZLT / S&P / -0.46% |
No dataRZLT / S&P / -27.11% |
| 2020-Q10/1 |
LoseRZLT / S&P -39.13% / -19.60% |
No dataRZLT / S&P / 3.47% |
No dataRZLT / S&P / -14.75% |
| 2019-Q40/1 |
LoseRZLT / S&P -23.33% / 9.07% |
No dataRZLT / S&P / 5.36% |
No dataRZLT / S&P / 2.99% |
| 2019-Q30/1 |
LoseRZLT / S&P -24.24% / 1.70% |
No dataRZLT / S&P / 5.02% |
No dataRZLT / S&P / 0.21% |
| 2019-Q20/1 |
LoseRZLT / S&P -1.00% / 4.30% |
No dataRZLT / S&P / 6.64% |
No dataRZLT / S&P / 8.65% |
| 2019-Q11/1 |
WinRZLT / S&P 122.22% / 13.65% |
No dataRZLT / S&P / 8.12% |
No dataRZLT / S&P / 14.29% |
| 2018-Q40/1 |
LoseRZLT / S&P -74.29% / -13.52% |
No dataRZLT / S&P / 9.05% |
No dataRZLT / S&P / 18.23% |
| 2018-Q30/1 |
LoseRZLT / S&P -22.22% / 7.71% |
No dataRZLT / S&P / 10.21% |
No dataRZLT / S&P / 19.06% |
| 2018-Q20/1 |
LoseRZLT / S&P -0.44% / 3.43% |
No dataRZLT / S&P / 9.03% |
No dataRZLT / S&P / 14.46% |
| 2018-Q10/1 |
LoseRZLT / S&P -48.93% / -0.76% |
No dataRZLT / S&P / 7.68% |
No dataRZLT / S&P / 12.46% |
| 2017-Q40/1 |
LoseRZLT / S&P -11.50% / 6.64% |
No dataRZLT / S&P / 7.03% |
No dataRZLT / S&P / 13.82% |
| 2017-Q30/1 |
LoseRZLT / S&P -11.50% / 4.48% |
No dataRZLT / S&P / 5.68% |
No dataRZLT / S&P / 17.57% |
| 2017-Q21/1 |
WinRZLT / S&P 13.00% / 3.09% |
No dataRZLT / S&P / 4.83% |
No dataRZLT / S&P / 17.74% |
| 2017-Q10/1 |
LoseRZLT / S&P 0.00% / 6.07% |
No dataRZLT / S&P / 3.67% |
No dataRZLT / S&P / 13.32% |
| 2016-Q40/1 |
LoseRZLT / S&P -25.93% / 3.82% |
No dataRZLT / S&P / 2.09% |
No dataRZLT / S&P / 7.05% |
| 2016-Q31/1 |
WinRZLT / S&P 35.00% / 3.85% |
No dataRZLT / S&P / 0.20% |
No dataRZLT / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | RZLT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -30.06% | 20.78% |
| Annualized return | -30.06% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | RZLT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -45.87% | 83.14% |
| Annualized return | -11.55% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | RZLT total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -89.29% | 319.30% |
| Annualized return | -20.02% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |